Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results